ID PDCD4_MOUSE Reviewed; 469 AA. AC Q61823; P97296; Q3T9A9; DT 31-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 15-JAN-2008, entry version 60. DE Programmed cell death protein 4 (Topoisomerase-inhibitor suppressed DE protein) (Protein MA-3). GN Name=Pdcd4; Synonyms=Ma3, Tis; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi; OC Muroidea; Muridae; Murinae; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY. RC STRAIN=ICR; TISSUE=Thymus; RX MEDLINE=96125207; PubMed=8543179; DOI=10.1016/0378-1119(95)00607-9; RA Shibahara K., Asano M., Ishida Y., Aoki T., Koike T., Honjo T.; RT "Isolation of a novel mouse gene MA-3 that is induced upon programmed RT cell death."; RL Gene 166:297-301(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Lymphoma; RX MEDLINE=97069646; PubMed=8912629; DOI=10.1006/bbrc.1996.1609; RA Onishi Y., Kizaki H.; RT "Molecular cloning of the genes suppressed in RVC lymphoma cells by RT topoisomerase inhibitors."; RL Biochem. Biophys. Res. Commun. 228:7-13(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY. RX MEDLINE=98382539; PubMed=9714845; DOI=10.1016/S0378-1119(98)00313-8; RA Onishi Y., Hashimoto S., Kizaki H.; RT "Cloning of the TIS gene suppressed by topoisomerase inhibitors."; RL Gene 215:453-459(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC STRAIN=BTBR T+ tf/J; RX PubMed=16682971; DOI=10.1038/ng1796; RA Clee S.M., Yandell B.S., Schueler K.M., Rabaglia M.E., Richards O.C., RA Raines S.M., Kabara E.A., Klass D.M., Mui E.T.-K., Stapleton D.S., RA Gray-Keller M.P., Young M.B., Stoehr J.P., Lan H., Boronenkov I., RA Raess P.W., Flowers M.T., Attie A.D.; RT "Positional cloning of Sorcs1, a type 2 diabetes quantitative trait RT locus."; RL Nat. Genet. 38:688-693(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC STRAIN=C57BL/6J, and NOD; TISSUE=Spleen, and Testis; RX PubMed=16141072; DOI=10.1126/science.1112014; RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K., RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., RA Davis M.J., Wilming L.G., Aidinis V., Allen J.E., RA Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L., RA Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M., RA Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R., RA Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G., RA di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G., RA Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M., RA Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E., RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., RA Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., RA Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., RA Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., RA Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J., RA Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L., RA Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K., RA Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P., RA Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O., RA Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G., RA Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M., RA Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C., RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y., RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., RA Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., RA Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., RA Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K., RA Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., RA Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., RA Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., RA Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., RA Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N., RA Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N., RA Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S., RA Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J., RA Hayashizaki Y.; RT "The transcriptional landscape of the mammalian genome."; RL Science 309:1559-1563(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Ebert L., Muenstermann E., Schatten R., Henze S., Bohn E., RA Mollenhauer J., Wiemann S., Schick M., Korn B.; RT "Cloning of mouse full open reading frames in Gateway(R) system entry RT vector (pDONR201)."; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC STRAIN=C57BL/6; TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA RT project: the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EIF4A1 AND RP EIF4A2. RX PubMed=12482958; DOI=10.1128/MCB.23.1.26-37.2003; RA Yang H.-S., Jansen A.P., Komar A.A., Zheng X., Merrick W.C., RA Costes S., Lockett S.J., Sonenberg N., Colburn N.H.; RT "The transformation suppressor Pdcd4 is a novel eukaryotic translation RT initiation factor 4A binding protein that inhibits translation."; RL Mol. Cell. Biol. 23:26-37(2003). RN [9] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=12894233; DOI=10.1038/sj.onc.1206710; RA Boehm M., Sawicka K., Siebrasse J.P., Brehmer-Fastnacht A., Peters R., RA Klempnauer K.-H.; RT "The transformation suppressor protein Pdcd4 shuttles between nucleus RT and cytoplasm and binds RNA."; RL Oncogene 22:4905-4910(2003). RN [10] RP FUNCTION. RX PubMed=16024603; DOI=10.1158/0008-5472.CAN-04-2119; RA Jansen A.P., Camalier C.E., Colburn N.H.; RT "Epidermal expression of the translation inhibitor programmed cell RT death 4 suppresses tumorigenesis."; RL Cancer Res. 65:6034-6041(2005). RN [11] RP X-RAY CRYSTALLOGRAPHY (1.15 ANGSTROMS) OF 320-469. RX PubMed=17060447; DOI=10.1128/MCB.00867-06; RA Laronde-Leblanc N., Santhanam A.N., Baker A.R., Wlodawer A., RA Colburn N.H.; RT "Structural basis for inhibition of translation by the tumor RT suppressor pdcd4."; RL Mol. Cell. Biol. 27:147-156(2007). CC -!- FUNCTION: Tumor suppressor. Inhibits tumor promoter-induced CC neoplastic transformation. Down-regulates the expression of CC MAP4K1, thus inhibiting events important in driving invasion, CC namely, MAPK85 activation and consequent JUN-dependent CC transcription. May play a role in apoptosis. Inhibits the helicase CC activity of EIF4A and cap-dependent translation. Binds RNA. CC -!- SUBUNIT: Interacts with EIF4A1 and EIF4A2. CC -!- INTERACTION: CC Q61655:Ddx19a; NbExp=1; IntAct=EBI-296473, EBI-296479; CC Q62448:Eif4g2; NbExp=1; IntAct=EBI-296473, EBI-296494; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Shuttles between CC nucleus and cytoplasm. Predominantly nuclear under normal growth CC conditions. Exported from the nucleus in the absence of serum. CC -!- TISSUE SPECIFICITY: Expressed ubiquitously. Highyly expressed in CC thymus and liver. Moderately expressed in brain, kidney and CC spleen; weakly in lung and heart. Expression is up- or down- CC regulated in response to apoptosis inducers. Regulated by many CC programmed cell death-inducing stimuli. CC -!- DOMAIN: Binds EIF4A1 via the MA3 domains (By similarity). CC -!- DISEASE: Decreases benign tumor development and malignant CC progression. CC -!- SIMILARITY: Belongs to the PDCD4 family. CC -!- SIMILARITY: Contains 2 MA3 domains. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D50465; BAA09056.1; -; mRNA. DR EMBL; D86344; BAA13072.1; -; mRNA. DR EMBL; AB010139; BAA32356.1; -; Genomic_DNA. DR EMBL; DQ479921; ABF51670.1; -; Genomic_DNA. DR EMBL; CT010188; CAJ18396.1; -; mRNA. DR EMBL; AK134366; BAE22118.1; -; mRNA. DR EMBL; AK172654; BAE43115.1; -; mRNA. DR EMBL; BC055739; AAH55739.1; -; mRNA. DR PIR; JC4523; JC4523. DR RefSeq; NP_035180.2; -. DR UniGene; Mm.1605; -. DR PDB; 2HM8; NMR; -; A=319-449. DR PDB; 2IOL; X-ray; 2.00 A; A/B=320-469. DR PDB; 2ION; X-ray; 1.57 A; A=320-469. DR PDB; 2IOS; X-ray; 1.76 A; A=320-469. DR PDB; 2NSZ; X-ray; 1.15 A; A=320-469. DR PDBsum; 2HM8; -. DR PDBsum; 2IOL; -. DR PDBsum; 2ION; -. DR PDBsum; 2IOS; -. DR PDBsum; 2NSZ; -. DR SMR; Q61823; 322-450. DR IntAct; Q61823; -. DR Ensembl; ENSMUSG00000024975; Mus musculus. DR GeneID; 18569; -. DR KEGG; mmu:18569; -. DR MGI; MGI:107490; Pdcd4. DR ArrayExpress; Q61823; -. DR CleanEx; MM_PDCD4; -. DR GermOnline; ENSMUSG00000024975; Mus musculus. DR GO; GO:0005829; C:cytosol; ISS:UniProtKB. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005515; F:protein binding; IPI:UniProtKB. DR GO; GO:0007569; P:cell aging; ISS:UniProtKB. DR GO; GO:0043508; P:negative regulation of JNK activity; ISS:UniProtKB. DR GO; GO:0016481; P:negative regulation of transcription; ISS:UniProtKB. DR InterPro; IPR003891; IF_eIF4G_MA3. DR Pfam; PF02847; MA3; 2. DR SMART; SM00544; MA3; 2. PE 1: Evidence at protein level; KW 3D-structure; Anti-oncogene; Apoptosis; Cell cycle; Cytoplasm; KW Nucleus; Phosphoprotein; Repeat; RNA-binding. FT CHAIN 1 469 Programmed cell death protein 4. FT /FTId=PRO_0000256520. FT DOMAIN 164 275 MA3 1. FT DOMAIN 327 440 MA3 2. FT MOTIF 58 64 Nuclear localization signal (Potential). FT MOTIF 448 454 Nuclear localization signal (Potential). FT MOD_RES 76 76 Phosphoserine (By similarity). FT MOD_RES 93 93 Phosphothreonine (By similarity). FT MOD_RES 457 457 Phosphoserine (By similarity). FT CONFLICT 232 232 S -> I (in Ref. 2; BAA32356 and 3; FT BAA13072). FT CONFLICT 369 369 V -> I (in Ref. 2; BAA32356 and 3; FT BAA13072). FT CONFLICT 414 414 D -> G (in Ref. 5; BAE43115). SQ SEQUENCE 469 AA; 51702 MW; 6883BCE5011692F1 CRC64; MDIENEQTLN VNPTDPDNLS DSLFSGDEEN AGTEEIKNEI NGNWISASTI NEARINAKAK RRLRKNSSRD SGRGDSVSDN GSEAVRSGVA VPTSPKGRLL DRRSRSGKGR GLPKKGGAGG KGVWGTPGQV YDVEEVDVKD PNYDDDQENC VYETVVLPLD ETAFEKTLTP IIQEYFEHGD TNEVAEMLRD LNLGEMKSGV PVLAVSLALE GKASHREMTS KLLSDLCGTV MSTNDVEKSF DKLLKDLPEL ALDTPRAPQL VGQFIARAVG DGILCNTYID SYKGTVDCVQ ARAALDKATV LLSMSKGGKR KDSVWGSGGG QQPVNHLVKE IDMLLKEYLL SGDISEAEHC LKELEVPHFH HELVYEAIVM VLESTGESAF KMILDLLKSL WKSSTITIDQ MKRGYERIYN EIPDINLDVP HSYSVLERFV EECFQAGIIS KQLRDLCPSR GRKRFVSEGD GGRLKPESY //